IBM’s Acquisition of Trusteer
August 15, 2013
On August 15, 2013, IBM announced it has entered into a definitive agreement to acquire Trusteer, a privately held company with locations in Boston, Massachusetts, and Tel Aviv, Israel. Cravath represented IBM in connection with this transaction, which is subject to customary closing conditions and is expected to close in the third quarter of 2013. Trusteer is a leading provider of advanced security and threat‑intelligence solutions that help protect organizations against financial fraud, malware and data breaches.
The Cravath team included partner George F. Schoen and associate Jane K. Manning on corporate matters; associates Jarrett R. Hoffman and Michelle M. Garrett on executive compensation and benefits matters; and partners Andrew W. Needham and J. Leonard Teti II and associates Christopher K. Fargo and William B. Abbott on tax matters. Summer associate Josh Ayal also worked on corporate matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1998, University of Chicago Law Schoolwith Honors
-
B.A., 1994, Cornell University
- New York
Education
Admitted In
- Photo
-
-
J.D., 2005, University of Virginia School of LawOrder of the Coif
-
A.B., 1999, Princeton Universitywith Honors
- New York
Education
Admitted In
- Photo
-
-
J.D., 2006, Columbia Law SchoolHarlan Fiske Stone; Michael Lynne Scholar
-
B.A., 2003, Boston CollegeHonors Program, cum laude
- New York
Education
Admitted In
- Photo
-
-
M.B.A., 1992, The Wharton School of the University of Pennsylvania
-
LL.M., 1990, Georgetown University Law Center
-
J.D., 1986, Georgetown University Law Center
-
B.A., 1982, University of Arizona College of Law
Education
Related News
Deals & Cases
October 04, 2024
DRI Healthcare Trust’s Acquisition of Payment Streams Based on the Cas9 Gene‑Editing Technology for CASGEVY®
On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.
Deals & Cases
September 10, 2024
IBM’s Acquisition of Accelalpha
On September 9, 2024, IBM announced its intent to acquire Accelalpha, a global Oracle services provider with deep expertise helping clients digitize core business operations and accelerate adoption of Oracle Cloud Applications. This acquisition expands IBM's Oracle consulting expertise in supply chain and logistics, finance, enterprise performance management and customer transformation. Cravath is representing IBM in connection with the transaction.
Deals & Cases
September 05, 2024
Frontier’s $20 Billion Acquisition by Verizon
On September 5, 2024, Verizon Communications Inc. and Frontier Communications Parent, Inc. (“Frontier”), the largest pure‑play fiber provider in the U.S., announced they have entered into a definitive agreement for Verizon to acquire Frontier in an all‑cash transaction valued at $20 billion. Cravath is representing Frontier in connection with the transaction.
Deals & Cases
May 07, 2024
Ashland’s Sale of its Nutraceuticals Business to Turnspire Capital Partners
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
